Simultaneous Estimation of Ketorolac Tromethamine and Moxifloxacin Hydrochloride in Ophthalmic Formulation by Hptlc Method Using DOE Approach

Ketorolac Tromethamine inhibits mainly the COX-2 enzyme pathway which leads to Analgesia and reduces inflammation and Moxifloxacin hydrochloride blocks the enzyme topoisomerase II. The Combination of these two drugs is used in the treatment of post-operative inflammatory condition. For estimation of Ketorolac Tromethamine and Moxifloxacin hydrochloride in bulk and in ophthalmic formulation, an HPTLC method was developed and validated which is accurate as well as precise. The method was optimized using Box- Behnken Design, Aluminium plate pre-coated with silica gel 60 F ₂₅₄ as stationary phase and Mobile Phase used was n – Butanol: Methanol: Ammonia (4.5:1:1 v/v/v). The analytical wavelength detected for both Ketorolac tromethamine and Moxifloxacin hydrochloride was 305 nm. The R _f value was found to be 0.74 and 0.28 with linearity range of 400–1200 ng/ band and 500–1500 ng/band for Ketorolac tromethamine and Moxifloxacin hydrochloride respectively.